Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 22, 2019 (7 years ago)

Losartan Potassium/HCTZ

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Losartan Potassium/HCTZ, 100 mg/12.5 mg Tablet, 90-Count bottle, Manufactured by Torrent Pharmaceuticals, Distributed by RemedyRepack, Inc. Indiana, PA, 15701-3570, NDC 70518-1560-00.

Affected NDC 70518-1560-00

Compare with the code on your package — it is the most precise check available.

Drug: Losartan Category: Blood Pressure Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Doxazosin
NDC 70518-1560
MESYLATE 2 mg/1 Tablet
Oral
Remedyrepack INC. Rx
Recalling firm
RemedyRepack Inc.
NDC code
70518-1560-00
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1270-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Losartan recalls

See all

Other recalls by RemedyRepack Inc.

All 2019 recalls
Class II · Moderate risk

Clindamycin HCl Capsule

CGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.

Ongoing cGMP deviation RemedyRePack Inc. D-0411-2025
Class II · Moderate risk

Carvedilol 25 mg Tablet

CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.

Terminated Nitrosamine impurity RemedyRepack Inc. D-0217-2025